A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

2019137 citationsJournal Articlehybrid Open Access

Authors

Li Sun · Queen Mary University of London

Adam R. Brentnall · Queen Mary University of London

Shreeya Patel · London School of Hygiene & Tropical Medicine

Diana S.M. Buist · Kaiser Permanente Washington Health Research Institute

Erin J. Aiello Bowles · Kaiser Permanente Washington Health Research Institute

D. Gareth Evans · University of Manchester

Diana Eccles

Abstract

This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.

Topics & Keywords

BRCA gene mutations in cancer Ovarian cancer diagnosis and treatment Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 5, Issue 12, pp. 1718-1718

DOI: 10.1001/jamaoncol.2019.3323

Field-Weighted Citation Impact: 13.95